Abivax SA, a clinical-stage biotechnology company, will be added to the Nasdaq Biotechnology Index on December 22, 2025. This marks a significant milestone for Abivax, reflecting their progress in advancing obefazimod through Phase 3 trials for ulcerative colitis. The NBI tracks the performance of biotechnology and pharmaceutical companies listed on Nasdaq, with eligibility requirements including market capitalization and trading volume. Abivax focuses on developing therapeutics to stabilize the immune response in patients with chronic inflammatory diseases, with their lead drug candidate, obefazimod, currently in Phase 3 clinical trials for ulcerative colitis.

Read more at GlobeNewswire: Abivax to be Added to Nasdaq Biotechnology Index